AZ's MedImmune gets cell-line patent; Novartis' Bexsero nabs innovation prize;

> AstraZeneca's ($AZN) MedImmune has received a U.S. patent for an optimized cell line used in flu vaccine production. Report

> Novartis' ($NVS) meningitis B vaccine, Bexsero, has won the U.K.'s Prix Galien innovation prize. Report

> Takeda has invested an undisclosed amount in Vaccine Safe Co. and will assist in the adoption of its vaccination management system. Release

> A team of New Zealand researchers has discovered new vaccine technology that can be used to treat asthma and other allergic diseases. Report

> After a U.S. visit from Indian Prime Minister Narendra Modi, the U.S. and India have agreed to collaborate on the development of affordable vaccines to fight dengue, malaria and tuberculosis. More

And Finally... Tracking children with fingerprint technology could improve vaccine accuracy, Michigan State University researchers say. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.